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Objective of this study is to investigate the potential of the learning vector quantizer neural network (LVQ-NN) classifier on various
diagnostic variables used in the modern cytopathology laboratory and to build an algorithm that may facilitate the classification
of individual cases. From all women included in the study, a liquid-based cytology sample was obtained; this was tested via HPV
DNA test, E6/E7 HPV mRNA test, and p16 immunostaining. The data were classified by the LVQ-NN into two groups: CIN-2 or
worse and CIN-1 or less. Half of the cases were used to train the LVQ-NN; the remaining cases (test set) were used for validation.
Out of the 1258 cases, cytology identified correctly 72.90% of the CIN-2 or worst cases and 97.37% of the CIN-1 or less cases, with
overall accuracy 94.36%. The application of the LVQ-NN on the test set allowed correct classification for 84.62% of the cases with
CIN-2 or worse and 97.64% of the cases with CIN-1 or less, with overall accuracy of 96.03%. The use of the LVQ-NNwith cytology
and the proposed biomarkers improves significantly the correct classification of cervical precancerous lesions and/or cancer and
may facilitate diagnosis and patient management.
1. Introduction
Approximately 7-8% of the total population screened in
the UK will have an abnormal smear [1, 2]; of those,
approximately 1.5–2% will present with high-grade and
5% with low-grade cytology. Only a small proportion of
women with low-grade cytology has underlying high-grade
histology. Even the cytological diagnosis of HSIL does not
necessarily reflect the histological presence of CIN2+ lesions.
HPV DNA test [3, 4] has proven its value in detecting
women with ASCUS cytology that may have an underlying
high-grade histology; however its high-positivity rates in
women with low-grade abnormalities fail its use as a triage
tool in that population. Accurate triage methods and tests
for women with both low- and high-grade cytology are
lacking. New emerging technologies and biomarkers such
as HPV DNA genotyping, E6&7 mRNA testing, and P16
immunostaining are continuously being investigated [5–12].
Various classification techniques such as neural networks
[13–18], discriminant analysis [16, 19, 20], decision trees
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[21, 22], or genetic algorithms [23] have been used in
medicine and, particularly, in diagnostic cytology. The
implementation of new diagnostic tools and molecular
techniques that are increasingly used in the diagnostic
cytology laboratory [24] may improve the accuracy of the
final diagnosis in comparison to that of cytology alone. The
application of neural networks on modern diagnostics might
be helpful in that respect.
This study aims to investigate the potential role of
learning vector quantizer neural networks (LVQNN) on var-
ious diagnostic variables used in the modern cytopathology
laboratory and build an algorithm that may facilitate the
classification of individual cases.
2. Materials and Methods
2.1. Inclusion Criteria and Interventions. This was a multi-
centric diagnostic study conducted at the Attikon University
Hospital and the University Hospital of Ioannina from 2007
till 2010. The population included a consecutive sample
of women with cytology taken as part of screening or
during colposcopy. A liquid-based cytology (LBC) sample
was obtained and was routinely prepared for cytological
assessment and the remaining material was used for testing
of specific biomarkers. These included the following tests:
cytology using the revised Bethesda classification system
(TBS2001 system) [25, 26], HPV arrays using the CLART
HUMAN PAPILLOMAVIRUS 2 (GENOMICA) that allows
simultaneous detection of 35 diﬀerent HPV genotypes by
PCR amplification of a fragment within the highly conserved
L1 region of the virus [27], NASBA assays [28] (NucliSENS
EasyQ HPV v1.0) that are used for the identification of
E6/E7 mRNA of the HPV types: 16, 18, 31, 33, and 45, the
PermiFlow (Invirion Diagnostics, LLC, Oak Brook, IL) that
allows the identification of E6/E7 mRNA expression of high-
risk HPV using FLOW cytometry technique [29], and finally
the immunocytochemical expression of p16 using the CINtec
Cytology Kit [30]. All these tests produce results that can be
used in a classification process and assess the whole cytologic
sample.
The histological diagnosis was the gold standard. All
women had histological diagnosis with colposcopically-
directed biopsies or LLETZ, apart from those with negative
cytology, colposcopy and HPV DNA test (clinically negative
cases). These were considered as having negative histology;
random biopsies were not taken.
2.2. Data Description and Preprocessing. The LVQ NN was
designed to classify the cases into two groups: GROUP 1
(clinically negative and CIN-1 or less at histology—these are
considered as negative) or GROUP 2 (CIN-2 or worse at
histology—these are considered as positive).
Before applying the LVQ NN, data have been processed
as shown in Table 1. Prior to feeding the data to the NN,
all variables were scaled at the same range (0 to 10) in
order to give all the same significance when processed by
the NN. Additionally, the dataset was randomly divided into
two sets: the training set used to train the NN, and the test
set, used for the NN evaluation. Stratified random sampling
was used to select approximately 50% of the cases from
each diagnostic category (GROUP 1 and GROUP 2) and
form the training set in order to preserve the structure of
the diagnostic groups in the divided sets. The LVQ NN is
developed by using the training set data; the trained model
was subsequently assessed by feeding the test set data and
evaluating its performance.
2.3. LVQ Neural Networks Basics. LVQ [31] is a supervised
neural network classifier. The available data is divided into
two sets, namely, the training and test sets and additionally
the category that these data belong to should be known in
advance.
During the training phase, the data is used along with
their allocated class and the classifier learns from this specific
data set. The LVQ NN creates partitions of the feature space.
Each partition is characterised by a vector in its center, called
the codebook vector; the class of this vector characterises
also the class of the complete partition. Only the training
set is used during the training phase, while the codebook
vectors are modified to represent the complete feature space.
Consequently, a passing of all the training vectors to the
classifier initiates the codebook vectors and subsequently the
training algorithm is applied during each of these passes.
Approximately 50–200 passes for all the training-set data are
required for the training of the classifier.
During the test phase, the trained NN is evaluated.
Each unknown case, being represented by a data vector is
presented to the network. The case class is determined by
the class of the partition, where the data vector resides.
The partition is defined by two steps, initially it is found
the codebook vector that is nearest to the unknown case
data vector and subsequently the partition of this nearest
codebook vector is considered to be similar to the partition
of the data vector.
LVQs can be expressed as NNs composed of two layers:
the first layer is a competitive layer having as inputs
the feature vectors and follows a second linear layer that
produces the NN output. The competitive layer learns
and subsequently classifies input vectors into subclasses
as described previously [31]. The linear layer assigns the
classes produced by the competitive layer into the target
classification classes as required by the specific problem. The
classes represented by the competitive layer represent various
subclasses formed in the feature space however belonging to
the same target class, the classes produced by the linear layer
(target classes) group the subclasses and produce from them
a single class. A schematic diagram of the LVQ NN structure
is presented in Figure 1. The competitive layer can be trained
with various versions of the LVQ algorithm, namely, LVQ1,
LVQ2.1, LVQ3, and optimized LVQ1 “OLVQ1” [32, 33].
The optimal number of codebook vectors, the number of
data passes and the optimal LVQ training algorithm variant
are determined according to the classifier performance on
the training set, that is, when there are satisfactory results
on the training set. The interested reader for the details
of the LVQ algorithm may consult the on line resources
[32, 34].
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Table 1: Variables used for the training of the LVQ NN classifier.
Variable name Variable description Variable value range
Cytological diagnosis
The result of the cytological examination expressed according to
bethesda system
6: SCC or ADENOCA,
5: HSIL, 4: ASC-H, 3: LSIL, 2:
ASCUS, 1: WNL
Binary HPV test The result of the HPV DNA test
Has a value of 0 if no HPV subtype
was found and 1 if there was found
even a single subtype
A6, A11, A16, A18, A26, A31,
A33, A35, A39, A40, A42, A43,
A44, A45, A51, A52, A53, A54,
A56, A58, A59, A61, A62, A66,
A68, A70, A71, A72, A73,
A81, A82, A83, A84, A85, A89
The existence of individual subtypes according to the HPV typing
examination
For each individual subtype: 1 if it
was found and 0 if it was not found
Number of HPV subtypes The number of HPV subtypes found by the HPV DNA test
Expressed as number of identified
subtypes
High-risk HPV subtypes
The number of high risk and very high risk subtypes found by the
HPV DNA test
Expressed as number of identified
high risk or very high risk subtypes
N16 The result of the E6/E7 mRNA test for HPV subtype 16 0 if negative and 1 if positive
N18 The result of the E6/E7 mRNA test for HPV subtype 18 0 if negative and 1 if positive
N31 The result of the E6/E7 mRNA test for HPV subtype 31 0 if negative and 1 if positive
N33 The result of the E6/E7 mRNA test for HPV subtype 33 0 if negative and 1 if positive
Flow test result
The result of the identification of E6/E7 mRNA expression of high
risk HPV using FLOW cytometry technique
0 if negative (positive expression
<1.5%) and 1 if positive (positive
expression >1.5
p16 result The result of the P16 immunocytochemical examination 0 if negative and 1 if positive
Histological examination The outcome of the histological examination 1 for positive or 0 for negative
Input vectors Subclasses
Target 
classes
Competitive
layer
Linear
layer
...
...
Figure 1: Schematic diagram of LVQ NN structure.
2.4. Statistical Analysis. The performance of cytology and
the LVQ NN was assessed; parameters such as sensitivity
(S), specificity (Sp), positive (PPV), negative predictive value
(NPV), and overall accuracy (OA) were calculated.
The accuracy of the LVQ NN in comparison to cytology
was assessed by comparing the areas under curve on the ROC
curves; the z-test was used for estimation of the standard
error.
In order to produce comparable results for cytology and
the LVQ NN, cases with cytology of ASC-H or worse and
histology of CIN-2 or worse were considered as true positive,
while cases with cytology of ASC-US or less and histology of
CIN-1 and less were considered true negative.
The Cochrane Q test [35] was applied on the results
of five new classifiers, trained and tested from scratch on
diﬀerent dataset splits. This test was used for the assessment
of the robustness of the proposed methodology,
We used open-source software implementing four ver-
sions of the LVQ algorithm (LVQ1, LVQ2.1, LVQ3, and
optimized LVQ1 “OLVQ1”), named LVQ PAK [32, 33] being
developed by Kohonen et al. [31, 32].
3. Results and Discussion
A total of 1258 samples were analyzed. The correlation of the
cytological diagnosis with the histological result is shown in
Table 2.
A total of 155 of those (12.3%) had CIN-2 or worse
histology, while 1103 (87.7%) CIN-1 or less. The detailed
distribution of the samples for the training and test sets
appear in Table 3. The correlation of the cytology and
histology is presented in Table 1. The ROC curve using the
CIN-1 histological result as a cutoﬀ point is presented in had
an area under curve (AUC) 0.913 with standard error (S.E.)
0.014. The accuracy parameters for cytology and the results
for the training and test set from the LVQ NN along with the
combined results for both sets appear in Table 4.
The LVQ training was based on the LVQ1 algorithm,
the number of neurons of the competitive layer was initially
started from 2 and, with a step of 1, increased up to 50.
The best results for classification of the training set were
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Table 2: Cross-tabulation of the histological and cytological findings.
Bethesda
Histological examination result
ADENO-CA SCC CIN-3 CIN-2 CIN-1 HPV HPV-suspect Negative Clinically negative Grand total
ADENO-CA 6 1 7
SCC 1 6 7
HSIL 8 45 42 15 2 7 119
ASC-H 1 1 2 2 3 9
LSIL 1 7 17 64 46 12 24 171
ASCUS 1 3 9 29 26 6 18 92
WNL 1 3 16 8 4 36 785 853
Grand total 9 16 57 73 124 84 22 88 785 1258
obtained using 17 neurons and no significant improvement
was achieved for more neurons. The addition of more
neurons in the competitive layer incorporates the danger of
over-training, as a result the NN may not perform well in
the test set. The output layer (linear layer) had two neurons;
one for each class. The optimal number of data passes was
50 (during each data pass, all available data of the training
set have been used for a training cycle), for more than
50 training cycles there was not improvement of the NN
performance on the training set. The other variations of
the LVQ algorithm (LVQ2.1, LVQ3, and OLVQ1) have been
tested to further improve already trained NNs however there
were produced similar or worst results.
The combined results for both the training and test set
indicate a sensitivity of 85.16%, a specificity of 98.01%, a
PPV of 85.71%, a NPV of 97.92% with an overall accuracy
of 96.42%. All these results favor the LVQ NN in comparison
to cytology alone, both for the complete (Table 4) as well as
for the individual training and test datasets (Table 3). The
comparison of the two ROC curves for cytology (AUC =
0.866 S.E. = 0.016) and the LVQ (AUC = 0.916 S.E. =
0.017) using histology as the gold standard, demonstrated
that the LVQ NN classifier results are superior to the
cytological diagnosis alone (z = −2.142, P < 0.05). The
comparison on the overall accuracy of standalone cytology
versus that of the LVQ classifiers favored the LVQ (χ2 = 5.6,
P < 0.05) as well.
In addition the LVQ NN system may identify more accu-
rately women that require immediate referral to colposcopy
but also reduce the number of women seen with clinically
insignificant lesions. For the LVQ NN, 2% will require
unnecessary colposcopy, whilst only 15% with a potentially
significant lesion will fail to be referred appropriately for
further colposcopic assessment. Using a cutoﬀ of ASCUS+
cytology for referral to colposcopy the rates are 23% and
2.6%, respectively, and 2.6% and 27% using for a cutoﬀ of
ASC-H+.
The stability of the method was subsequently assessed
using the z statistics on the two ROC curves (classifier versus
histology for each one) for the LVQ training versus the
test set. The lack of significant diﬀerence in the classifier’s
performance for the training and test set in the ROC curves
(Training Set AUC = 0.927 S.E. = 0.023, Test set AUC =
0.905 S.E. = 0.025, z = 0.648 with P > 0.1) and in the
overall accuracy of the training and test set (χ2 = 0.072 with
P > 0.1) proved the system’s stability.
The robustness of the method was further evaluated
with five new experiments. The dataset was de novo divided
into “new” training and test sets. The stability in the
performance of the “new” classifiers was evaluated after de
nuovo retraining each time. The results are shown in Table 5.
The probability that all the five classifiers would provide
similar outcomes for an individual case was high (Q = 3.51,
DF = 4) as calculated by the Cochrane Q test.
This study shows that LVQNN has superior performance
than cytology alone for the detection of high-grade lesions
in a mixed population (women attending screening and
colposcopy). It has higher sensitivity and specificity than
cytology at the threshold of ASC-H+ and much higher
specificity than cytology at the threshold of ASCUS, even
though its sensitivity was lower. Our results from the
comparison of the training and test set were nonsignificant
and suggest that the use of LVQ NN appears to provide an
accurate prediction of the histological outcome that could
guide further management. It therefore seems that the LVQ
NN is a reliable tool for the diagnosis of high-grade lesions.
The challenge is finding an appropriate role for its use in
the cervical cancer prevention eﬀorts. The high costs of the
biomarkers and the reduced sensitivity over cytology at the
commonly used threshold for screening (ASCUS+) makes
the LVQ NN probably unsuitable for screening purposes.
However its high specificity and its overall superiority over
higher cytological thresholds suggest a possible role in triage
of minor or even major cytological abnormalities.
Despite the advances of the last decade, there is still lack
of consensus on the optimal management of women pre-
senting with a low-grade cytological abnormality (LSIL) [36–
39]. A substantial proportion of these women may actually
harbor a high-grade lesion (HSIL). In our population, 14.6%
of women with LSIL had underlying CIN2+ at histology. The
so far available management options for low-grade abnor-
malities include either conservative surveillance with repeat
cytology or immediate referral to colposcopy [40]. Surveil-
lance has an inherent risk of noncompliance and default from
further surveillance [41], which may put women with clini-
cally significant lesions at potential risk of invasive cervical
cancer. Immediate colposcopy can conversely lead to over-
loading of colposcopy clinics with financial consequences
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Table 4: Performance of the LVQ NN for the training set, test set and in total, and Cytological performance in our material.
LVQ
training set
LVQ
test set
LVQ
training and test sets
Cytology
ASC-H+ versus CIN2+
Cytology
ASCUS+ versus CIN2+
Sensitivity 85.71% 84.62% 85.16% 72.90% 97.42%
Specificity 98.37% 97.64% 98.01% 97.37% 76.97%
PPV 88.00% 83.54% 85.71% 79.58% 37.28%
NPV 98.01% 97.82% 97.92% 96.24% 99.53%
FPR 1.63% 2.36% 1.99% 2.63% 23.03%
FNR 14.29% 15.38% 14.84% 27.10% 2.58%
OA 96.82% 96.03% 96.42% 94.36% 79.49%
Table 5: Performance of the five LVQ NNs trained and tested for the robustness test (cumulative results for the training and test set).
Classifier 1 Classifier 2 Classifier 3 Classifier 4 Classifier 5
Sensitivity 85.81% 85.16% 85.16% 85.81% 85.81%
Specificity 98.01% 97.46% 97.28% 97.73% 97.55%
PPV 85.81% 82.50% 81.48% 84.18% 83.13%
NPV 98.01% 97.91% 97.90% 98.00% 98.00%
FPR 1.99% 2.54% 2.72% 2.27% 2.45%
FNR 14.19% 14.84% 14.84% 14.19% 14.19%
OA 96.50% 95.95% 95.79% 96.26% 96.10%
to clinical and health resources as well as overintervention
and overtreatment with long-term adverse future pregnancy
outcomes or even increased perinatal mortality in women
of reproductive age [2, 42, 43]. A more accurate assessment
of the underlying risk would be undoubtedly beneficial for
patients as well as health economies.
Similarly, current practice and guidelines advocate
immediate referral and commonly histological confirmation
and treatment for all high-grade lesions. A small, albeit
significant, proportion of those cases (up to 30%) may,
however, have a low-grade or even normal histology. In our
study 20.4% of women with ASC-H+ cytology had CIN-1
or less. Reliable triage methods are lacking. An attempt in
that scientific direction is the development of the concept
of a “scoring system”, in order to identify individual risk for
CIN2+ regardless of the cytologic and colposcopic findings.
A combination of the proposed HPV-related biomarkers as
well as other epidemiological data, available from women’s
history, such as demographic characteristics, sexual behavior,
and potential cofactor information (smoking, condom use,
etc.), in addition to cytology and colposcopy, could identify
individual risk estimation for CIN2+, CIN3+ or even
invasive disease [40, 44].
Although HPV DNA testing has been proposed as
a reliable method of triage of ASCUS cytology [3, 4],
new biomarkers, such as HPV DNA status, mRNA E6/E7
expression of HPV -16, -18, -31, -33, and -45, E6/E7 mRNA
expression of high-risk HPV types and p16 immunocyto-
chemistry may prove useful and improve the accuracy of
diagnosis [36, 38, 39]. The incorporation of those new tests
in neural networks may allow easier and more accurate
interpretation of the results.
Our study has certain limitations. The population under
study is mixed, that is, women attending for screening and
women referred for colposcopy because of abnormal smears.
Secondly in our study a large number of variables was used,
which although validated as relevant in the diagnosis of
CIN2+ in the literature, some of themmight eventually prove
to have minimal weight in the final diagnosis and could be
excluded.
Therefore a future research direction could be studying
the performance of LVQ NN in a strictly defined population
consisting of women with LSIL smears only and assess its
accuracy indices in triage. Also as the use of all the biomark-
ers in all situations will increase costs to a nonacceptable
level, research should be directed at finding diﬀerent com-
binations with a selection of those tests with similar accuracy
at reduced cost. Studies assessing also the cost-eﬀectiveness
of such an approach on a screening program are required.
4. Conclusions
These preliminary results suggest that the incorporation of
new tests and combinations of biomarkers using artificial
intelligence methods end especially the LVQ NN may signif-
icantly improve the accuracy of diagnosis. Such an approach
may reduce the overload of colposcopy clinics and guide
tailored management and intervention. The results should
be further assessed in larger datasets in order to confirm
the reproducibility of those findings and the applicability in
situations of specific interest.
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